Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jul 12;7(28):44841-44847.
doi: 10.18632/oncotarget.8601.

How do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studies

Sara Pusceddu  1   2 , Filippo De Braud  1   2 , Giuseppe Lo Russo  1   2 , Laura Concas  1   2 , Daniela Femia  1   2 , Claudio Vernieri  1   2 , Alice Indini  1   2 , Barbara Formisano  1   2 , Roberto Buzzoni  1   2
Affiliations

How do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studies

Sara Pusceddu et al. Oncotarget. .

Abstract

In the last five years, everolimus has demonstrated efficacy in the treatment of neuroendocrine tumors (NETs) of different origins; its efficacy and safety were explored in the RADIANT trials, the last of which (RADIANT-4) has been recently published (December 2015). Overall, evidence collected from the RADIANT studies holds promise to change clinical practice for the treatment of NETs.In this paper, we comment on the role of everolimus within the therapeutic algorithm for NETs treatment, based on the systematic analysis of the RADIANT trials and our experience.

Keywords: everolimus; neuroendocrine tumors.

PubMed Disclaimer

Conflict of interest statement

There is no conflict of interest.

Figures

Figure 1
Figure 1. Treatment algorithm – proposed by the authors – for the treatment of lung carcinoids (Panel A) and of midgut G1-2 carcinoids (Panel B) after the publication of the RADIANT-4 trial
Figure 1
Figure 1. Treatment algorithm – proposed by the authors – for the treatment of lung carcinoids (Panel A) and of midgut G1-2 carcinoids (Panel B) after the publication of the RADIANT-4 trial
See this image and copyright information in PMC

References

    1. Fraenkel M, Kim MK, Faggiano A, Valk GD. Epidemiology of gastroenteropancreatic neuroendocrine tumours. Best Pract Res Clin Gastroenterol. 2012;26:691–703. - PubMed
    1. Panzuto F, Rinzivillo M, Fazio N, de Braud F, Luppi G, Zatelli MC, Lugli F, Tomassetti P, Riccardi F, Nuzzo C, Brizzi MP, Faggiano A, Zaniboni A, et al. Real-world study of everolimus in advanced progressive neuroendocrine tumors. Oncologist. 2014;19:966–74. - PMC - PubMed
    1. Barbieri F, Albertelli M, Grillo F, Mohamed A, Saveanu A, Barlier A, Ferone D, Florio T. Neuroendocrine tumors: insights into innovative therapeutic options and rational development of targeted therapies. Drug Discov Today. 2014;19:458–68. - PubMed
    1. Manfredi GI, Dicitore A, Gaudenzi G, Caraglia M, Persani L, Vitale G. PI3K/Akt/mTOR signaling in medullary thyroid cancer: a promising molecular target for cancer therapy. Endocrine. 2015;48:363–70. - PubMed
    1. Yao JC, Phan AT, Chang DZ, Wolff RA, Hess K, Gupta S, Jacobs C, Mares JE, Landgraf AN, Rashid A, Meric-Bernstam F. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol. 2008;26:4311–8. - PMC - PubMed

Publication types

MeSH terms